Table 4.

Analysis of clinical factors affecting OS of radiotherapy and chemotherapy for intermediate and advanced cervical squamous cell carcinoma.

Clinical factors	cases	Univariate analysis		Multivariate analysis
		HR(95% CI)	P-value	HR (95% CI)	P-value
group			<0.001		<0.001
Chemoradiotherapy sensitive group	44	ref		ref
Chemoradiotherapy resistance group	43	4.44 (2.09-9.43)		5.67 (2.37-13.56)
ASPH			0.0448		0.2602
low	39	ref		ref
high	48	2.06 (1.02-4.18)		1.60 (0.71-3.62)
age(year)	87	0.99 (0.95-1.03)	0.564	0.97 (0.92- 1.03)	0.3411
Stage			0.243		0.3155
IIb-IIIa	26	ref		ref
≥IIIb	61	1.60 (0.73-3.53)		1.60 (0.64-4.04)
Tumor diameter			0.0161		0.0735
<=4cm	36	ref		ref
>4cm	51	2.33 (1.12-4.81)	0.0229	3.22 (1.29-8.04)	0.0124
hemoglobin	87	1.00 (0.98-1.01)	0.776	1.01 (0.99-1.03)	0.2566
NLR	87	1.27 (1.06-1.52)	0.0086	1.02 (0.79-1.31)	0.9067
PLR	87	1.00 (1.00-1.00)	0.203	1.00 (1.00-1.00)	0.8209
Lymph node metastasis			0.018		0.3182
No	52	ref		ref
Yes	35	2.20 (1.15-4.22)		1.51 (0.67-3.38)
The total duration of radiotherapy (month)
<=8	39	ref		ref
> 8	48	2.06 (1.03-4.12)	0.0411	2.82 (1.24-6.40)	0.0132
Number of concurrent chemotherapy courses (weeks)	87	0.94 (0.79-1.12)	0.469	0.82 (0.64-1.04)	0.1052
Adjuvant chemotherapy course (weeks)	87	0.99 (0.80-1.23)	0.946	0.97 (0.74-1.26)	0.7997